Jane Street Group LLC Takes Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI)

Jane Street Group LLC acquired a new stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 33,437 shares of the company’s stock, valued at approximately $38,000. Jane Street Group LLC owned approximately 0.13% of Calidi Biotherapeutics at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of CLDI. Geode Capital Management LLC raised its stake in shares of Calidi Biotherapeutics by 304.0% in the fourth quarter. Geode Capital Management LLC now owns 160,018 shares of the company’s stock valued at $184,000 after acquiring an additional 120,406 shares in the last quarter. HighTower Advisors LLC purchased a new position in Calidi Biotherapeutics in the fourth quarter valued at $118,000. Virtu Financial LLC purchased a new position in Calidi Biotherapeutics in the fourth quarter valued at $84,000. RS Crum Inc. purchased a new position in Calidi Biotherapeutics in the fourth quarter valued at $47,000. Finally, Red Wave Investments LLC increased its holdings in Calidi Biotherapeutics by 74.0% in the fourth quarter. Red Wave Investments LLC now owns 80,828 shares of the company’s stock valued at $93,000 after buying an additional 34,367 shares during the last quarter. 12.53% of the stock is currently owned by institutional investors and hedge funds.

Calidi Biotherapeutics Price Performance

NYSE:CLDI opened at $0.33 on Tuesday. The business’s fifty day moving average price is $0.43 and its 200 day moving average price is $0.92. Calidi Biotherapeutics, Inc. has a 12 month low of $0.32 and a 12 month high of $3.89.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.